Table 3.
Basal and FSK-induced I sc without inhibitor and with acetazolamide (10−4 M bilaterally, 10 min prior to FSK) pretreatment in NBCe1 WT and KO intestinal segments
| FSK-induced △I sc without inhibitor (μEq cm−2 h−1) | FSK-induced △I sc in the presence of acetazolamide (μEq cm−2 h−1) | |
|---|---|---|
| Duodenum NBCe1+/+ | 5.65 ± 0.24 | 4.58 ± 0.59 |
| Duodenum NBCe1−/− | 3.17 ± 0.46*& | 5.51 ± 0.92 |
| Jejunum NBCe1+/+ | 6.92 ± 0.60 | 5.40 ± 0.39 |
| Jejunum NBCe1−/− | 3.69 ± 0.52*& | 5.14 ± 0.85 |
| Cecum NBCe1+/+ | 9.90 ± 0.86 | 3,33 ± 0.57 |
| Cecum NBCe1−/− | 5.31 ± 1.09* | 2.55 ± 0.46 |
| Prox.Colon NBCe1+/+ | 3.05 ± 0.33* | Not done |
| Prox.Colon NBCe1−/− | 4.52 ± 0.19 |
*P < 0.05, comparison between NBCe1 WT and KO mice; % P < 0.05, comparison in NBCe1 WT mice between the absence and presence of acetazolamide; &P < 0.05, comparison of FSK-induced △I sc in NBCe1 KO mice between the absence and presence of acetazolamide. n = 6-8